GU Cancers 2022 | Results from URO-12 trial of niraparib maintenance therapy for advanced urothelial carcinoma

Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses results from the Phase II URO-12 trial (NCT03945084) of niraparib as maintenance therapy for patients with advanced urothelial carcinoma who have undergone first-line platinum-based chemotherapy. 58 patients were involved in the study, of whom 39 were randomised to the experimental arm and 19 to the control arm. There was no significant improvement in progression-free survival (PFS) with niraparib maintenance after a median follow-up of 8.5 months, compared to the control of best supportive care. Prof. Di Maio also discusses the results of the exploratory molecular analysis performed on the tumor tissue of 47 patients, looking at homologous recombination repair gene mutations. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.